Contact | Print version | PDF version | Send article | RSS-Feed

NicOx announces U.S. phase 2a results for PF-03187207 and gives an update on continuing NO-prostaglandin program

07 May 2008 - NicOx S.A. announced the results of a U.S. phase 2 study, conducted by its partner Pfizer Inc, which compared the safety and efficacy of various doses of PF-03187207 to XalatanŽ (latanoprost) 0.005% in patients with primary open-angle glaucoma and ocular hypertension. The higher doses of PF-03187207 demonstrated a clinically significant reduction in diurnal intraocular pressure (IOP) from baseline and the highest dose showed consistently more IOP lowering than XalatanŽ 0.005%, at all study visits and at all individual time points, suggesting a beneficial effect of nitric oxide donation. PF-03187207 is a nitric oxide-donating prostaglandin analog, which is covered by the companies' August 2004 agreement.
 
On the primary endpoint at 28 days, PF-03187207 showed a 12% improvement over XalatanŽ 0.005% which did not reach statistical significance. However, a statistically significant advantage over XalatanŽ 0.005% was observed on a number of secondary endpoints (p<0.05).
 
Pfizer has taken the decision not to launch a global phase 3 development program for PF-03187207. Nevertheless, Pfizer has reaffirmed its commitment to the ongoing joint research program with NicOx, which aims to identify the most active nitric oxide-donating prostaglandin analogs for development on a global basis.